Stock Price Prediction

COCP stock is currently trading at $2.16, down significantly due to disappointing results from its Phase 2a influenza study, which reported low infectivity rates. The bearish sentiment is driven by concerns over the drug's efficacy and extended trial timelines, which have dampened investor confidence. Despite a "Strong Buy" rating from HC Wainwright with a $7 price target, the stock's near-term outlook remains weak unless positive trial updates emerge.

COCP stock is currently bearish, trading at $2.16, down 33.5%. The decline is driven by disappointing results from its Oral PB2 inhibitor CC-42344, leading to an extended Phase 2a influenza study. This negative development has significantly impacted investor sentiment, pushing the stock lower.

The market consensus for COCP's eps in the upcoming quarter is projected to be approximately $0.57 USD.